2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation is a research paper published in EP Europace (2021). On theSindex it has a DataRank of 0. It has been cited 1,091 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute for Health Research (NIHR)
Grant: NF-SI-0616-10010
National Institute for Health Research (NIHR)
Grant: NIHR201320
Bayer Pharma AG
Bristol-Myers Squibb
NIH
Daiichi-Sankyo Europe GmbH
Pfizer Alliance
MeSH Terms
Keywords
Additional file 1 of Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
Additional file 1 of Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
Additional file 1 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 1 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 2 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 2 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 3 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 3 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 4 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 4 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 5 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 5 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 6 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 6 of Overall performance of a drug–drug interaction clinical decision support system: quantitative evaluation and end-user survey
Additional file 1 of Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
Additional file 1 of Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
Additional file 2 of Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
Additional file 2 of Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
Additional file 3 of Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
Additional file 3 of Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences